Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0U9HM
|
|||
| Former ID |
DIB016273
|
|||
| Drug Name |
GSK-1322888
|
|||
| Synonyms |
1322888
Click to Show/Hide
|
|||
| Indication | Gastroparesis [ICD-11: DA41.00; ICD-9: 536.3] | Phase 1 | [1] | |
| Company |
GlaxoSmithKline plc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Motilin receptor (MLNR) | Target Info | Agonist | [1] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01294566) FTIH to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses of GSK1322888 in Healthy Caucasian and Japanese Volunteers. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.